NovaBridge Biosciences (NBP) Preferred Stock Liabilities (2018 - 2020)

NovaBridge Biosciences (NBP) has reported Preferred Stock Liabilities for 3 consecutive years, with $1.3 billion the latest figure, recorded in Q4 2020.

• Quarterly Preferred Stock Liabilities rose 196.68% year-over-year to $1.3 billion in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $1.3 billion (up 196.68% YoY) and the FY2020 annual result came in at $1.3 billion, up 4894.77% from the prior year.
• Preferred Stock Liabilities was little changed at $1.3 billion in Q4 2020 per NBP's latest filing, from $1.3 billion in the prior quarter.
• Over the last five years, Preferred Stock Liabilities for NBP reached as high as $1.3 billion in Q2 2020 and fell as low as $421.6 million in Q4 2018.
• A 3-year average of $868.8 million and a median of $873.5 million in 2019 frame the typical range for Preferred Stock Liabilities.
• Annual changes were most pronounced in 2019 — Preferred Stock Liabilities grew 4.45% — and 2020, when it soared 196.68%.
• Year by year, Preferred Stock Liabilities stood at $421.6 million in 2018, then grew by 4.45% to $440.4 million in 2019, then jumped by 196.68% to $1.3 billion in 2020.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $1.3 billion, $1.3 billion, and $440.4 million for Q4 2020, Q2 2020, and Q4 2019 respectively.